/biz/ - Business & Finance

TCON

Tracon partner 3D Medicines granted orphan designation for envafolimab 3D Medicines was granted FDA orphan designation for envafolimab as a treatment of biliary tract cancer, according to a post to the FDA website. On Dec. 20, 2019, Tracon Pharmaceuticals announced that it had signed a collaborative partnership agreement with 3D Medicines for the development of envafolimab, also known as KN035, a PD-L1 single-domain antibody administered by subcutaneous injection, for development in soft tissue sarcoma in North America.

... and it’s Only the beginning here. Hell news hit at almost close so the stock only spiked ≈50% so far. Not even an overreaction compared to bio’s +100% trends for short term. Either way it’s going up from here long term, no matter what happens short. It is now your turn anon, make your move.